Acrivon (ACRV): Dana dhuwit perusahaan

Logo grafis Acrivon Therapeutics (ACRV)

Acrivon Therapeutics (ACRV) creates personalized tumor treatments leveraging predictive diagnostics and capital support. The company is implementing the APAM AI system to develop targeted inhibitors, demonstrating significant scientific potential. A breakthrough in AP3 precision proteomics and the preparation of CHK1/2 releases are transforming diagnostics. The cash-on-hand metric illustrates the balance between liquidity and capital efficiency, where 0.08 shows the current value of the metric.

Dana dhuwit perusahaan: Acrivon (ACRV) kanggo 28.04.2023 - 21.11.2026

ACRV (Acrivon): rincian analitis lan laporan miturut indikator

- kuotasi lan prakiraan analis:
Analisis kabeh metrik perusahaan:Acrivon Pharma
Produk merek Acrivon Therapeutics Inc

For the biotech startup Acrivon Therapeutics (ACRV), which lacks revenue and depends on clinical trial results, its liquidity cushion serves as the primary guarantee of survival. The current cash on hand stands at 0.08, allowing for a real-time assessment of the business's discounted value and a comparison of existing financial reserves against market capitalization to determine the level of downside protection for the capital.